Menu
Oslo, Norway, 2 May 2025
Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") the Company on 24 April 2025 whereby it was disclosed that the Company's annual meeting resolved ("AGM"), among other things, the approval of a restricted share units ("RSU") program.
At the AGM, the shareholders approved the remuneration to the Company's current board of directors whereby the board members were given the choice to receive their remuneration, or a part thereof, for the period from the AGM to the annual general meeting of 2026, in the form of restricted share units ("RSU"), as a part of the Company's RSU program. The allocation of RSUs has today been made.
The number of RSUs allocated to each board member has been determined based on the NOK value for the RSU-selected portion of the total compensation for the board member. The compensation is divided by the subscription price of NOK 2.4295, equal to the 10-day volume weighted average prior the general meeting. A total of 274,401 RSUs has been allocated to the following board members:
Primary insider notifications pursuant to the market abuse regulation article 19 are attached. This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
